Results 1 to 10 of about 13,011 (272)
Deferasirox improved iron homeostasis and hematopoiesis in ovariectomized rats with iron accumulation [PDF]
Scientific ReportsMenopause is a natural biological aging process characterized by the loss of ovarian follicular function and decrease estrogen levels. These hormonal fluctuations are associated with increased iron levels, which ultimately lead to iron accumulation. This
Niloofar Honari +4 more
doaj +3 more sources
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023 Background Ferroptosis, an iron‐dependent form of regulated cell death, is a major cell death mode in myocardial ischemia reperfusion (I/R) injury, along with mitochondrial permeability transition‐driven necrosis, which is inhibited by cyclosporine A ...
Kosei Ishimaru +15 more
doaj +2 more sources
Effects of Deferasirox in Alzheimer’s Disease and Tauopathy Animal Models [PDF]
Biomolecules, 2022 The accumulation of iron may contribute to Alzheimer’s disease (AD) and other tauopathies. The iron chelator desferrioxamine slows disease progression in AD patients.
Ping Kwan, Amy Ho, Larry Baum
openalex +2 more sources
Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome [PDF]
Anais Brasileiros de Dermatologia, 2017 Deferasirox is an iron chelator agent used in the treatment of diseases with iron overload, such as thalassemia and myelodysplastic syndrome. Although the majority of adverse reactions of deferasirox involve gastrointestinal symptoms and increase in ...
Asude Kara Polat +3 more
doaj +3 more sources
Haematologica, 2023 CALYPSO (clinicaltrials gov. Identifier: NCT02435212), a randomized, open-label, multicenter, phase II study evaluated the compliance, clinical benefits, and safety of deferasirox granules and dispersible tablets (DT) in pediatric patients with iron ...
Ali T. Taher +8 more
doaj +2 more sources
Pharmaceutics, 2021 Pancreatic cancer is a malignant disease with high mortality and poor prognosis due to lack of early diagnosis and low treatment efficiency after diagnosis.
Yan Zhu, Hongyan Zhu, Tianqing Liu
exaly +2 more sources
Molecules, 2021 Deferasirox is an orally active, lipophilic iron chelating drug used on thousands of patients worldwide for the treatment of transfusional iron overload. The essential transition metals iron and copper are the primary catalysts of reactive oxygen species
Viktor A. Timoshnikov +4 more
doaj +2 more sources
Crushed deferasirox
American journal of hematology/oncology, 2022 Iron associated with end-organ retar-dation, problems with sexual development, and an increased risk of mortality. 1,2 Treatment adherence is crucial for optimizing long-term iron chelation therapy (ICT) in this patient in turn depends on the mode of ...
Yasser Wali +11 more
openalex +2 more sources
Deferasirox Nanosuspension Loaded Dissolving Microneedles for Intradermal Delivery [PDF]
Pharmaceutics, 2022 Microneedles are minimally invasive systems that can deliver drugs intradermally without pain and bleeding and can advantageously replace the hypodermal needles and oral routes of delivery.
Hafsa Shahid Faizi +9 more
openalex +2 more sources
Journal of the Formosan Medical Association, 2013 The newly available iron chelator deferasirox (Exjade, Novartis) is expected to provide better long-term clinical outcomes and improved quality of life for patients with thalassemia than its predecessor, deferoxamine (Desferal, Novartis), because of its ...
Wan-Ling Ho +8 more
doaj +2 more sources